OncoMatch/Clinical Trials/NCT04974866
Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma
Is NCT04974866 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies EGFR-TK Inhibitor for carcinoma, adenoid cystic.
Treatment: EGFR-TK Inhibitor — There is no clinical study on epidermal growth factor receptor tyrosine kinase inhibitors has been systematically conducted in adenoid cystic carcinoma. This is a phase II study EGFR TKIs in adenoid cystic carcinoma to evaluate its efficacy in this disease.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: chemotherapy
previously treated with chemotherapy or local treatment (e,g transarterial chemoembolization)
Cannot have received: chemotherapy
Exception: last treatment was at least 4 weeks prior to baseline assessment
Prior chemotherapy ... within 4 weeks prior to study entry except palliative radiotherapy to non-target lesions (within 2 weeks prior to study entry)
Cannot have received: radiation therapy
Exception: palliative radiotherapy to non-target lesions (within 2 weeks prior to study entry)
Prior ... radiation therapy ... within 4 weeks prior to study entry except palliative radiotherapy to non-target lesions (within 2 weeks prior to study entry)
Cannot have received: surgery
Prior ... surgery within 4 weeks prior to study entry
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify